Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Lancet Oncol. 2014 Nov 12;15(13):1481–1492. doi: 10.1016/S1470-2045(14)70486-3

Table 5.

Multiple Cox regressions for post-relapse survival

Hazard ratio (95% CI) p-value
Randomized treatment: XELOX or FOLFOX vs leucovorin and fluorouracil 0·92 (0·81–1·05) 0·23
Sex (women vs men) 1·02 (0·90–1·16) 0·71
Age (<70 years vs ≥70 years) 0·70 (0·60–0·81) <0·0001
T stage (T1–2 vs T3–4) 0·82 (0·61–1·10) 0·19
N stage (N1 vs N2) 0·73 (0·64–0·83) <0·0001

XELOX=capecitabine plus oxaliplatin. FOLFOX=leucovorin and fluorouracil plus oxaliplatin. T stage=tumour stage. N stage=nodal stage.